Synta Announces Results From Final Analysis of the GALAXY-1 Trial of Ganetespib in NSCLC

[Business Wire] – Synta Pharmaceuticals Corp. today announced final results from the GALAXY-1 trial, a global, randomized, multi-center study designed to identify the patients with advanced non-small cell lung cancer with adenocarcinoma histology most li more

View todays social media effects on SNTA

View the latest stocks trending across Twitter. Click to view dashboard

See who Synta is hiring next, click here to view